Natalizumab

Elgemtumab (anti-ERBB3) is a fully human IgG monoclonal antibody. Elgemtumab (anti-ERBB3) can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor

Elgemtumab (anti-ERBB3) is a fully human IgG monoclonal antibody. Elgemtumab (anti-ERBB3) can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor

Elotuzumab is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural

Emactuzumab (anti-CSF1R) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab (anti-CSF1R) has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab

Emactuzumab (anti-CSF1R) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab (anti-CSF1R) has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab

Emactuzumab (anti-CSF1R) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab (anti-CSF1R) has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab

Emactuzumab (anti-CSF1R) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab (anti-CSF1R) has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab

Emibetuzumab (anti-MET) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab (anti-MET) shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and

Emibetuzumab (anti-MET) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab (anti-MET) shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and

Emibetuzumab (anti-MET) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab (anti-MET) shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and

Emibetuzumab (anti-MET) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab (anti-MET) shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and

Enfortumab (anti-NECTIN4) is a monoclonal antibody targeting Nectin-4. Enfortumab (anti-NECTIN4) can used for researching urothelial cancer.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin Level&lt: 1.0EU/mg.